| http://www.w3.org/ns/prov#value | - Documentation (8) In determining whether a change in the drug benefit price is in the public interest, the executive officer may require the manufacturer to supply any information, other than personal information, that the executive officer considers relevant, and the manufacturer shall comply with the request. 2006, c. 14, s. 28.
|
